XTRA:RDC
XTRA:RDCConsumer Retailing

Assessing Redcare Pharmacy (XTRA:RDC) Valuation After Strong 2025 Sales Update

Sales update puts Redcare Pharmacy in focus Redcare Pharmacy (XTRA:RDC) is back on investors’ radar after reporting fourth quarter 2025 group sales of €794 million, compared with €675 million a year earlier, alongside full year sales of €2.9b versus €2.4b in 2024. See our latest analysis for Redcare Pharmacy. Despite the strong sales update, Redcare Pharmacy’s share price has had a weak run, with a 90 day share price return of 24.46% decline and a 1 year total shareholder return of 45.89%...
XTRA:MBG
XTRA:MBGAuto

Is Mercedes-Benz Group (XTRA:MBG) Attractive After Recent Share Price Weakness?

If you are wondering whether Mercedes-Benz Group is attractively priced right now, this article walks through what the current share price really reflects. The stock closed at €58.82, with returns of a 2.6% decline over 7 days, a 1.7% decline over 30 days, a 5.0% decline year to date, a 16.0% return over 1 year, 13.2% over 3 years and 65.6% over 5 years. This gives you a mix of shorter term weakness and longer term gains to think about. Recent coverage around Mercedes-Benz Group has focused...
XTRA:BC8
XTRA:BC8IT

Will AI-Driven Managed Services Shift Bechtle's (XTRA:BC8) Revenue Mix Toward More Resilient Contracts?

Recent coverage indicates that Bechtle AG’s AI-related services are helping drive higher-margin projects and growing recurring managed-service bookings across its European customer base. This shift toward AI-enabled, service-based work highlights how Bechtle may be reshaping its revenue mix toward more resilient, contract-driven income streams. Next, we’ll examine how rising AI-driven, higher-margin managed-service demand could influence Bechtle’s existing investment narrative and risk...
XTRA:SZU
XTRA:SZUFood

Will Südzucker's (XTRA:SZU) Return to Quarterly Profit Amid Falling Sales Change Its Risk Narrative?

Südzucker AG has reported past third-quarter 2025 results showing sales of €2,156 million, down from €2,374 million a year earlier, while net income improved to €3 million from a net loss of €119 million and basic loss per share from continuing operations narrowed to €0.02 from €0.62. Over the first nine months, sales fell to €6,355 million from €7,466 million and the company moved from €23 million net income to a €59 million net loss, highlighting that the recent quarterly profit comes...
XTRA:FRE
XTRA:FREHealthcare

How Fresenius Kabi’s T Cell Automation Deal At Fresenius SE KGaA (XTRA:FRE) Has Changed Its Investment Story

Earlier this week, Fresenius Kabi and TQ Therapeutics announced a development agreement giving Fresenius Kabi exclusive rights to integrate TQ’s proprietary cell selection technology into its Cue Cell Processing System for automated, high‑purity T cell isolation in cell and gene therapy manufacturing. This collaboration could materially enhance Fresenius’s position in advanced therapies by pairing TQ’s affinity-based cell isolation with Fresenius Kabi’s automation capabilities, potentially...
XTRA:TKMS
XTRA:TKMSAerospace & Defense

A Look At TKMS & Co KGaA (XTRA:TKMS) Valuation After New AI Teaming Agreement With Cohere

Why the TKMS & Co KGaA teaming move with Cohere matters for investors TKMS & Co KGaA (XTRA:TKMS) is drawing attention after signing a teaming agreement with Cohere to explore advanced AI across the Canadian Patrol Submarine Program, including decision support, training, and secure naval interfaces. The collaboration focuses on research, prototyping, and evaluation activities that are designed to meet Royal Canadian Navy and Government of Canada security and compliance requirements, while...
XTRA:EBK
XTRA:EBKElectric Utilities

How EnBW’s Exit From UK Offshore Wind And €1.20bn Impairment At EnBW (XTRA:EBK) Has Changed Its Investment Story

EnBW Energie Baden-Württemberg has in the past decided to discontinue its UK offshore wind projects Mona and Morgan after missing government Contracts for Difference support and judging the schemes uneconomic amid higher supply chain costs, lower power prices, higher interest rates and implementation risks, triggering a €1.20 billion impairment in its 2025 accounts while keeping its adjusted EBITDA outlook unchanged. This move highlights how EnBW is willing to walk away from large-scale...